Clinical Trial: A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Brief Summary: The purpose of this study is to assess the safety and efficacy of Tavilermide Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

Detailed Summary:
Sponsor: Mimetogen Pharmaceuticals USA, Inc.

Current Primary Outcome:

  • Corneal Fluorescein Staining [ Time Frame: Day 57 ]
  • Ocular Discomfort [ Time Frame: Day 57 ]


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • Corneal Fluorescein Staining [ Time Frame: Day 15 ]
  • Ocular Surface Disease Index [ Time Frame: Day 57 ]
  • Ocular Dryness [ Time Frame: 8 weeks ]


Original Secondary Outcome: Same as current

Information By: Mimetogen Pharmaceuticals USA, Inc.

Dates:
Date Received: December 16, 2015
Date Started: December 2015
Date Completion:
Last Updated: March 24, 2017
Last Verified: September 2016